Revolution Medicines ($RVMD) Insider Trading & Smart Money Activity
Revolution Medicines, Inc. ($RVMD) has 26 insider trades, 3 13F position changes and 11 analyst ratings on file. In the last 12 months on the open market, no insider bought and 12 insiders sold ($27.29M), net -$27.29M.
- Insider buyers (12 mo)
- 0
- Insider sellers (12 mo)
- 12
- Net insider $ (12 mo)
- -$27.29M
- Congress trades (12 mo)
- 0
- 13F moves on file
- 3
- Analyst ratings on file
- 11
RVMD insider buying and selling by quarter
| Quarter | Insider buys | Insider sales | Congress buys / sales | 13F added / cut |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
| Q2 2026 | 0 | 6 · $16.02M | 0 / 0 | 2 / 1 |
| Q3 2026 | 0 | 13 · $11.27M | 0 / 0 | 0 / 0 |
| Q4 2026 | 0 | 0 | 0 / 0 | 0 / 0 |
Insider buys and sales count open-market trades only (Form 4 codes P and S). Grants, option exercises and tax withholding are left out.
All RVMD insider, congress, 13F and analyst activity
| Date | Source | Who | Action | Shares | Value / amount | ΔOwn | 1W | 1M | 6M | Filing | Story |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Analyst | William Blair | Reiterates to Outperform | Read | ||||||||
| Analyst | Needham | Reiterates to Buy | PT $275 | Read | |||||||
| Analyst | RBC Capital | Reiterates to Outperform | PT $260 | Read | |||||||
| Analyst | RBC Capital | Reiterates to Outperform | PT $259 | +0.6% | — | ||||||
| Analyst | Truist Securities | Reiterates to Buy | PT $240 | -3.7% | — | ||||||
| Insider | Sandler Alan B.Chief Development Officer | Sell (Open-market sale) 10b5-1 | 6.31K sh | $1.28M | -2.3% | — | |||||
| Analyst | Brookline Capital | Reiterates to Buy | PT $318 | +2.9% | — | ||||||
| Insider | Mancini AnthonyChief Global Commercialization Officer | Sell (Open-market sale) 10b5-1 | 3.12K sh | $625.89K | +0.8% | — | |||||
| Insider | Cislini JeffSVP & General Counsel | Sell (Open-market sale) 10b5-1 | 765 sh | $158.60K | +0.8% | — | |||||
| Insider | Mancini AnthonyChief Global Commercialization Officer | Sell (Open-market sale) 10b5-1 | 587 sh | $117.40K | +3.0% | — | |||||
| Insider | Anderson Elizabeth MDirector | Sell (Open-market sale) 10b5-1 | 10.14K sh | $1.96M | +6.0% | — | |||||
| Analyst | B of A Securities | Reiterates to Buy | PT $265 | +4.7% | — | ||||||
| Insider | Mancini AnthonyChief Global Commercialization Officer | Sell (Open-market sale) 10b5-1 | 1.76K sh | $347.40K | +7.3% | — | |||||
| Insider | Sandler Alan B.Chief Development Officer | Sell (Open-market sale) 10b5-1 | 341 sh | $67.94K | -2.6% | -9.2% | — | ||||
| Insider | Mancini AnthonyChief Global Commercialization Officer | Sell (Open-market sale) 10b5-1 | 1.77K sh | $353.45K | -2.6% | -9.2% | — | ||||
| Insider | Kelsey Stephen MichaelSenior Advisor to the Chief Executive Officer | Sell (Open-market sale) 10b5-1 | 5.57K sh | $1.11M | -2.6% | -9.2% | — | ||||
| Insider | Horn Margaret AChief Operating Officer | Sell (Open-market sale) 10b5-1 | 4.97K sh | $989.61K | -2.6% | -9.2% | — | ||||
| Insider | Goldsmith Mark APresident and Chief Executive Officer | Sell (Open-market sale) 10b5-1 | 13.99K sh | $2.79M | -2.6% | -9.2% | — | ||||
| Insider | Cislini JeffSVP & General Counsel | Sell (Open-market sale) 10b5-1 | 3.37K sh | $670.63K | -2.6% | -9.2% | — | ||||
| Insider | Anders JackChief Financial Officer | Sell (Open-market sale) 10b5-1 | 4.05K sh | $807.51K | -2.6% | -9.2% | — | ||||
| Analyst | Truist Securities | Reiterates to buy | PT $210 | +1.7% | +2.6% | Read | |||||
| Analyst | Needham | Reiterates to buy | PT $235 | -1.4% | -6.1% | Read | |||||
| Insider | Jack AndersChief Financial Officer | Sell (Open-market sale) 10b5-1 | 20K sh | $3.37M | +10.4% | +11.5% | Read | ||||
| Insider | Jack AndersChief Financial Officer | Buy (Option exercise) | 20K sh | +10.4% | +11.5% | Read | |||||
| Insider | Sushil Patel | Buy (Grant or award) | 3.13K sh | +9.3% | +10.7% | Read | |||||
| Insider | Lorence Kim | Buy (Grant or award) | 3.13K sh | +9.3% | +10.7% | Read | |||||
| Insider | Flavia Borellini | Buy (Grant or award) | 1.19K sh | +9.3% | +10.7% | Read | |||||
| Insider | Margaret HornChief Operating Officer | Sell (Option exercise) | 29.60K sh | +7.6% | +18.0% | — | |||||
| Insider | Margaret HornChief Operating Officer | Buy (Option exercise) | 29.60K sh | $803.46K | +7.6% | +18.0% | — | ||||
| Insider | Kelsey Stephen MichaelPresident, Research and Development | Sell (Open-market sale) 10b5-1 | 4.17K sh | $651.80K | +8.3% | +14.4% | — | ||||
| Insider | Mark GoldsmithPresident and Chief Executive Officer | Sell (Open-market sale) 10b5-1 | 10.02K sh | $1.56M | +8.3% | +14.4% | Read | ||||
| Insider | Jeff CisliniGeneral Counsel | Sell (Open-market sale) 10b5-1 | 2.16K sh | $336.75K | +8.3% | +14.4% | — | ||||
| Insider | Jack AndersChief Financial Officer | Sell (Open-market sale) 10b5-1 | 2.72K sh | $424.96K | +8.3% | +14.4% | Read | ||||
| Insider | Margaret HornChief Operating Officer | Sell (Open-market sale) 10b5-1 | 60.40K sh | $9.67M | +3.6% | +15.2% | Read | ||||
| Insider | Margaret HornChief Operating Officer | Sell (Option exercise) | 10K sh | +9.2% | +23.3% | — | |||||
| Analyst | Evercore ISI Group | Reiterates to buy | PT $220 | +9.4% | +29.6% | — | |||||
| Analyst | Evercore ISI Group | Reiterates to buy | PT $220 | +9.4% | +29.6% | Read | |||||
| 13F | Farallon Capital Management | Reduced | -978K sh | $2.62B | +4.1% | +9.9% | — | ||||
| 13F | Baker Bros. Advisors | Added | +100K sh | $1.84B | +4.1% | +9.9% | — | ||||
| 13F | Avoro Capital Advisors | Added | +174.44K sh | $451.59M | +4.1% | +9.9% | Read |
1W / 1M / 6M = how RVMD moved from the trade or filing date.
Insider trading in RVMD: who is buying and selling
| Insider | Role | Trades | Open-market net | Shares held | Last trade |
|---|---|---|---|---|---|
| Sandler Alan B. | Chief Development Officer | 2 | -$1.34M | Sep 29, 2026 | |
| Mancini Anthony | Chief Global Commercialization Officer | 4 | -$1.44M | Sep 25, 2026 | |
| Cislini Jeff | SVP & General Counsel | 2 | -$829.23K | Sep 25, 2026 | |
| Anderson Elizabeth M | Director | 1 | -$1.96M | Sep 22, 2026 | |
| Kelsey Stephen Michael | Senior Advisor to the Chief Executive Officer | 2 | -$1.76M | Sep 16, 2026 | |
| Horn Margaret A | Chief Operating Officer | 1 | -$989.61K | Sep 16, 2026 | |
| Goldsmith Mark A | President and Chief Executive Officer | 1 | -$2.79M | Sep 16, 2026 | |
| Anders Jack | Chief Financial Officer | 1 | -$807.51K | Sep 16, 2026 | |
| Jack Anders | Chief Financial Officer | 3 | -$3.79M | Jun 24, 2026 | |
| Sushil Patel | 1 | — | Jun 18, 2026 | ||
| Lorence Kim | 1 | — | Jun 18, 2026 | ||
| Flavia Borellini | 1 | — | Jun 18, 2026 | ||
| Margaret Horn | Chief Operating Officer | 4 | -$9.67M | Jun 17, 2026 | |
| Mark Goldsmith | President and Chief Executive Officer | 1 | -$1.56M | Jun 16, 2026 | |
| Jeff Cislini | General Counsel | 1 | -$336.75K | Jun 16, 2026 |
Institutions moving RVMD (13F)
Analyst ratings on RVMD
| Date | Firm | Action | Rating | Price target | 1W | 1M | 6M | Story |
|---|---|---|---|---|---|---|---|---|
| William Blair | Reiterates | Outperform | Read | |||||
| Needham | Reiterates | Buy | $275 | Read | ||||
| RBC Capital | Reiterates | Outperform | $259 → $260 | Read | ||||
| RBC Capital | Reiterates | Outperform | $251 → $259 | +0.6% | — | |||
| Truist Securities | Reiterates | Buy | $239 → $240 | -3.7% | — | |||
| Brookline Capital | Reiterates | Buy | $318 | +2.9% | — | |||
| B of A Securities | Reiterates | Buy | $225 → $265 | +4.7% | — | |||
| Truist Securities | Reiterates | buy | $210 | +1.7% | +2.6% | Read | ||
| Needham | Reiterates | buy | $235 | -1.4% | -6.1% | Read | ||
| Evercore ISI Group | Reiterates | buy | $220 | +9.4% | +29.6% | — |
Frequently asked questions
Are RVMD insiders buying or selling?
Over the last 12 months 0 insiders made 0 open-market purchases worth $0 and 12 insiders made 19 open-market sales worth $27.29M, a net -$27.29M.
What is the latest insider trade in RVMD?
Sandler Alan B., Chief Development Officer filed a sell (open-market sale) of 6.31K sh worth $1.28M on Sep 29, 2026.
Which institutions changed their RVMD positions?
Recent 13F filers moving the stock include Farallon Capital Management, Baker Bros. Advisors and Avoro Capital Advisors.
Other biotechnology stocks
Data comes from public SEC Form 4 and 13F filings and STOCK Act disclosures. Dates are the trade or filing date reported. This page is for research only and is not investment advice.
Get a text when insiders, Congress or big funds trade a stock.
Free. Reply STOP anytime.